VRC/NIAID/NIH, 40 Convent Drive, Bethesda, MD 20892, USA.
Curr Opin Virol. 2012 Jun;2(3):324-9. doi: 10.1016/j.coviro.2012.04.003. Epub 2012 May 4.
Because of high case fatality proportions, person-to-person transmission, and potential use in bioterrorism, the development of a vaccine against ebolavirus remains a top priority. Although no licensed vaccine or treatment against ebolavirus is currently available, progress in preclinical testing of countermeasures has been made. Here, we will review ebolavirus vaccine candidates and considerations for their use in humans and wild apes.
由于埃博拉病毒的高病死率、人际传播和潜在的生物恐怖主义用途，开发针对埃博拉病毒的疫苗仍然是当务之急。尽管目前尚无针对埃博拉病毒的许可疫苗或治疗方法，但在对抗措施的临床前测试方面已经取得了进展。在这里，我们将回顾埃博拉病毒疫苗候选物及其在人类和野生猿类中的使用考虑因素。
